BellBrook Labs, an innovative developer of drug discovery tools, is launching a new Transzyme Methyltransferase Assay kit for EZH2, an oncogenic histone methyltransferase that is being targeted for non-small cell lung cancer and other types of cancer. The new Transzyme EZH2 Assay combines the company’s Transcreener HTS assay technology with Reaction Biology’s purified EZH2 enzyme to provide a complete methyltransferase assay solution for inhibitor high throughput screening (HTS) and profiling.
Madison, WI (PRWEB) August 28, 2013 -- BellBrook Labs is continuing their successful collaboration with Reaction Biology to accelerate epigenetics drug discovery with the launch of a new Transzyme Methyltransferase Assay kit for histone methyltransferase EZH2. The Transzyme EZH2 kit combines all of the required EZH2 enzyme reaction components and BellBrook’sTranscreener EPIGEN Methyltransferase Assay detection reagents into a well-defined kit that is pre-calibrated to produce HTS-quality data. With the addition of EZH2, the expanding line of Transzyme Methyltransferase Assays now ...
